Trial reportJournal of endocrinological investigation2026
Hypoglycaemia and other risks of ramadan fasting in patients with primary adrenal insufficiency: A prospective controlled trial using 24-hour glucose monitoring.
Trial report in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Risks of Intermittent Fasting in Patients With Primary Adrenal Insufficiency
Risks of Ramadan Fasting in Patients With Primary Adrenal Insufficiency Treated With Prednisolone.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPatients with primary adrenal insufficiency (PAI) are at increased risk of hypoglycaemia and dehydration. We aimed to evaluate the risk of complications, particularly hypoglycaemia, associated with Ramadan fasting (RF) in patients with PAI, using continuous glucose monitoring (CGM).
methodsIn this prospective, randomised, crossover, case-control study, we evaluated the prevalence of complications using clinical, biological and CGM data during RF and non-fasting days in 30 patients with PAI. All participants were treated with hydrocortisone and fludrocortisone and received a therapeutic education.
results27 women and 3 men, mean age: 44.8±9.2 years, median duration of PAI: 7 years (4-10.5). Median daily doses were 20 mg of hydrocortisone and 50 µg of fludrocortisone. The prevalence of complications was 67% during RF and 23% outside RF (p = 0.001). Eleven patients (37%) broke the fast due to the occurrence of a complication. Signs of hypoglycaemia were reported by 37% of the patients during RF and 3% outside fasting (p = 0.002). Mean interstitial glucose levels were lower during fasting than outside fasting. The prevalence of CGM-detected hypoglycaemia (71% vs. 63%, p = 1.000), time spent below 3.9 and 3.0 mmol/l, and blood pressure levels were not different between RF and non-fasting days. Urea levels increased during RF but remained within normal limits.
conclusionComplications were frequent during RF in patients with PAI. Hypoglycaemia was frequent both during and outside RF. Registered on Clinical Trials on February 28th, 2024, under the identifier NCT06299020.
Indexed as
Identifiers
41108503What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.